Literature DB >> 15254282

Timing and magnitude of increases in levothyroxine requirements during pregnancy in women with hypothyroidism.

Erik K Alexander1, Ellen Marqusee, Jennifer Lawrence, Petr Jarolim, George A Fischer, P Reed Larsen.   

Abstract

BACKGROUND: Hypothyroidism during pregnancy has been associated with impaired cognitive development and increased fetal mortality. During pregnancy, maternal thyroid hormone requirements increase. Although it is known that women with hypothyroidism should increase their levothyroxine dose during pregnancy, biochemical hypothyroidism occurs in many. In this prospective study we attempted to identify precisely the timing and amount of levothyroxine adjustment required during pregnancy.
METHODS: Women with hypothyroidism who were planning pregnancy were observed prospectively before and throughout their pregnancies. Thyroid function, human chorionic gonadotropin, and estradiol were measured before conception, approximately every two weeks during the first trimester, and monthly thereafter. The dose of levothyroxine was increased to maintain the thyrotropin concentration at preconception values throughout pregnancy.
RESULTS: Twenty pregnancies occurred in 19 women and resulted in 17 full-term births. An increase in the levothyroxine dose was necessary during 17 pregnancies. The mean levothyroxine requirement increased 47 percent during the first half of pregnancy (median onset of increase, eight weeks of gestation) and plateaued by week 16. This increased dose was required until delivery.
CONCLUSIONS: Levothyroxine requirements increase as early as the fifth week of gestation. Given the importance of maternal euthyroidism for normal fetal cognitive development, we propose that women with hypothyroidism increase their levothyroxine dose by approximately 30 percent as soon as pregnancy is confirmed. Thereafter, serum thyrotropin levels should be monitored and the levothyroxine dose adjusted accordingly. Copyright 2004 Massachusetts Medical Society

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15254282     DOI: 10.1056/NEJMoa040079

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  88 in total

1.  Treatment-refractory hypothyroidism.

Authors:  Abdulaziz Ramadhan; Michael Tamilia
Journal:  CMAJ       Date:  2011-12-12       Impact factor: 8.262

2.  Thyroid function during controlled ovarian hyperstimulation as part of in vitro fertilization.

Authors:  Clarisa R Gracia; Christopher B Morse; Grace Chan; Samantha Schilling; Maureen Prewitt; Mary D Sammel; Susan J Mandel
Journal:  Fertil Steril       Date:  2012-01-18       Impact factor: 7.329

3.  Thyroid gland: Early adjustment of levothyroxine treatment in pregnancy.

Authors:  Shiao Y Chan
Journal:  Nat Rev Endocrinol       Date:  2010-10       Impact factor: 43.330

4.  Thyroid nodule and differentiated thyroid cancer management in pregnancy. An Italian Association of Clinical Endocrinologists (AME) and Italian Thyroid Association (AIT) Joint Statement for Clinical Practice.

Authors:  E Papini; R Negro; A Pinchera; R Guglielmi; A Baroli; P Beck-Peccoz; P Garofalo; M P Pisoni; M Zini; R Elisei; L Chiovato
Journal:  J Endocrinol Invest       Date:  2010-07-13       Impact factor: 4.256

Review 5.  Perchlorate, iodine and the thyroid.

Authors:  Angela M Leung; Elizabeth N Pearce; Lewis E Braverman
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2010-02       Impact factor: 4.690

6.  Development of Graves' hyperthyroidism during the early phase of pregnancy in a patient with pre-existing and long-standing Hashimoto's hypothyroidism.

Authors:  M Gola; M Doga; G Mazziotti; S Bonadonna; A Giustina
Journal:  J Endocrinol Invest       Date:  2006-03       Impact factor: 4.256

Review 7.  Hypopituitarism and successful pregnancy.

Authors:  Xue Du; Qing Yuan; Yanni Yao; Zengyan Li; Huiying Zhang
Journal:  Int J Clin Exp Med       Date:  2014-12-15

8.  A case of lymphocytic panhypophysitis (LPH) during pregnancy.

Authors:  Yasuyuki Arai; Koichiro Nabe; Hiroki Ikeda; Sachiko Honjo; Yoshiharu Wada; Yoshiyuki Hamamoto; Kazuhiro Nomura; Tomokazu Aoki; Toshiaki Sano; Hiroyuki Koshiyama
Journal:  Endocrine       Date:  2007-09-26       Impact factor: 3.633

9.  Pharmacogenetics and other reasons why drugs can fail in pregnancy: higher dose or different drug?

Authors:  David M Haas; Mary DʼAlton
Journal:  Obstet Gynecol       Date:  2012-11       Impact factor: 7.661

Review 10.  Autoimmune thyroid disease in pregnancy: a review.

Authors:  Juan C Galofre; Terry F Davies
Journal:  J Womens Health (Larchmt)       Date:  2009-11       Impact factor: 2.681

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.